Mindfulness Meditation in Glioma Patients
Malignant Glioma
About this trial
This is an interventional supportive care trial for Malignant Glioma focused on measuring Malignant Glioma, Mindfulness, Dina Randazzo, Meditation, Katherine Barnett Peters
Eligibility Criteria
Inclusion Criteria:
- ≥ 18 years of age
- NCCN distress scale ≥ 4 OR at least one of the following problems indicated on the NCCN distress thermometer worksheet: depression, fears, nervousness, sadness, worry, loss of interest in usual activities, sleep, memory, or fatigue
- Karnofsky Performance Status (KPS) ≥ 70
- Patient must have histologically confirmed, newly diagnosed WHO grade III or IV malignant glioma
- Patient must be prior to a planned 6-week standard of care chemoradiation regimen
- Patient can speak, read, and write English
- Patient has access to a telephone for mindfulness training
- Patient has access to internet
Exclusion Criteria:
- Patients previously or currently practicing or participating in mindfulness meditation practice
- Intermittent or active psychosis
- Psychiatric hospitalization within the last 6 months
- Hospitalized in a rehab facility within the last 6 months for substance abuse
Sites / Locations
- Duke University Medical Center
Arms of the Study
Arm 1
Experimental
Mindfulness meditation
Newly diagnosed malignant glioma patients will participate in six 1-hour mindfulness sessions over the phone, followed by one 1-hour in-person mindfulness session. Patients will complete various Quality of Life questionnaires and distress measuring tools prior to initiating the mindfulness sessions, at the clinic visit following the mindfulness intervention, and ~2 months after completing the mindfulness intervention. Additionally, patients will be provided with supplemental materials including website references and guided audiotape meditations to guide their individual practice outside of the weekly guided sessions.